Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Nov;74(2):151–161.

The interleukins in acquired disease.

M Malkovský 1, P M Sondel 1, W Strober 1, A G Dalgleish 1
PMCID: PMC1541799  PMID: 3066538

Full text

PDF
151

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asherson G. L., Colizzi V., Malkovský M., Colonna-Romano G., Zembala M. The role of interleukin-2 as one of the determinants of the balance between immunity and unresponsiveness. Folia Biol (Praha) 1985;31(6):387–395. [PubMed] [Google Scholar]
  2. Auron P. E., Webb A. C., Rosenwasser L. J., Mucci S. F., Rich A., Wolff S. M., Dinarello C. A. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7907–7911. doi: 10.1073/pnas.81.24.7907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Azuma C., Tanabe T., Konishi M., Kinashi T., Noma T., Matsuda F., Yaoita Y., Takatsu K., Hammarström L., Smith C. I. Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue. Nucleic Acids Res. 1986 Nov 25;14(22):9149–9158. doi: 10.1093/nar/14.22.9149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Billiau A., Van Damme J., Opdenakker G., Fibbe W. E., Falkenburg J. H., Content J. Interleukin 1 as a cytokine inducer. Immunobiology. 1986 Sep;172(3-5):323–335. doi: 10.1016/S0171-2985(86)80114-0. [DOI] [PubMed] [Google Scholar]
  5. Blick M., Sherwin S. A., Rosenblum M., Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987 Jun 1;47(11):2986–2989. [PubMed] [Google Scholar]
  6. Borzy M. S. Interleukin 2 production and responsiveness in individuals with acquired immunodeficiency syndrome and the generalized lymphadenopathy syndrome. Cell Immunol. 1987 Jan;104(1):142–153. doi: 10.1016/0008-8749(87)90015-3. [DOI] [PubMed] [Google Scholar]
  7. Brandt S. J., Peters W. P., Atwater S. K., Kurtzberg J., Borowitz M. J., Jones R. B., Shpall E. J., Bast R. C., Jr, Gilbert C. J., Oette D. H. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 7;318(14):869–876. doi: 10.1056/NEJM198804073181401. [DOI] [PubMed] [Google Scholar]
  8. Brenner M. K., North M. E., Chadda H. R., Newton C. A., Malkovsky M., Webster A. D., Farrant J. The role of B cell differentiation factors and specific T cell help in the pathogenesis of primary hypogammaglobulinemia. Eur J Immunol. 1984 Nov;14(11):1021–1027. doi: 10.1002/eji.1830141111. [DOI] [PubMed] [Google Scholar]
  9. Chen B. P., Malkovsky M., Hank J. A., Sondel P. M. Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb. Cell Immunol. 1987 Dec;110(2):282–293. doi: 10.1016/0008-8749(87)90123-7. [DOI] [PubMed] [Google Scholar]
  10. Clutterbuck E., Shields J. G., Gordon J., Smith S. H., Boyd A., Callard R. E., Campbell H. D., Young I. G., Sanderson C. J. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol. 1987 Dec;17(12):1743–1750. doi: 10.1002/eji.1830171210. [DOI] [PubMed] [Google Scholar]
  11. Colizzi V. In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice. Infect Immun. 1984 Jul;45(1):25–28. doi: 10.1128/iai.45.1.25-28.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Colizzi V., Malkovsky M. Augmentation of interleukin-2 production and delayed hypersensitivity in mice infected with Mycobacterium bovis and fed a diet supplemented with vitamin A acetate. Infect Immun. 1985 May;48(2):581–583. doi: 10.1128/iai.48.2.581-583.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Colizzi V., Malkovsky M., Lang G., Asherson G. L. In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by the injection of interleukin-2. Immunology. 1985 Dec;56(4):653–658. [PMC free article] [PubMed] [Google Scholar]
  14. Crawford R. M., Finbloom D. S., Ohara J., Paul W. E., Meltzer M. S. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol. 1987 Jul 1;139(1):135–141. [PubMed] [Google Scholar]
  15. Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984 Dec 20;312(5996):763–767. doi: 10.1038/312763a0. [DOI] [PubMed] [Google Scholar]
  16. Dalgleish A., Malkovský M. Advances in human retroviruses. Adv Cancer Res. 1988;51:307–360. doi: 10.1016/s0065-230x(08)60225-0. [DOI] [PubMed] [Google Scholar]
  17. DeFreitas E. C., Sandberg-Wollheim M., Schonely K., Boufal M., Koprowski H. Regulation of interleukin 2 receptors on T cells from multiple sclerosis patients. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2637–2641. doi: 10.1073/pnas.83.8.2637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Depper J. M., Leonard W. J., Krönke M., Waldmann T. A., Greene W. C. Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J Immunol. 1984 Oct;133(4):1691–1695. [PubMed] [Google Scholar]
  19. Dinarello C. A. Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). Year Immunol. 1986;2:68–89. [PubMed] [Google Scholar]
  20. Donahue R. E., Wang E. A., Stone D. K., Kamen R., Wong G. G., Sehgal P. K., Nathan D. G., Clark S. C. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. 1986 Jun 26-Jul 2Nature. 321(6073):872–875. doi: 10.1038/321872a0. [DOI] [PubMed] [Google Scholar]
  21. Essery G., Feldmann M., Lamb J. R. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology. 1988 Jul;64(3):413–417. [PMC free article] [PubMed] [Google Scholar]
  22. Finkelman F. D., Katona I. M., Urban J. F., Jr, Snapper C. M., Ohara J., Paul W. E. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9675–9678. doi: 10.1073/pnas.83.24.9675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Flomenberg N., Welte K., Mertelsmann R., Kernan N., Ciobanu N., Venuta S., Feldman S., Kruger G., Kirkpatrick D., Dupont B. Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol. 1983 Jun;130(6):2644–2650. [PubMed] [Google Scholar]
  24. Forni G., Giovarelli M., Santoni A., Modesti A., Forni M. Tumour inhibition by interleukin-2 at the tumour/host interface. Biochim Biophys Acta. 1986 Dec 17;865(3):307–327. doi: 10.1016/0304-419x(86)90020-x. [DOI] [PubMed] [Google Scholar]
  25. Gao L. Q., Asherson G. L., Malkovsky M. Increased lymphokine activated killer (LAK) activity in the regional lymph nodes of mice following immunization with contact sensitizing agents. Clin Exp Immunol. 1987 Oct;70(1):217–221. [PMC free article] [PubMed] [Google Scholar]
  26. Gao L., Malkovský M., Webster A. D., Asherson G. L. Impaired lymphokine-activated killer-cell activity in patients with hypogammaglobulinaemia. Lancet. 1985 Aug 10;2(8450):340–340. doi: 10.1016/s0140-6736(85)90394-0. [DOI] [PubMed] [Google Scholar]
  27. Gillis S., Crabtree G. R., Smith K. A. Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol. 1979 Oct;123(4):1624–1631. [PubMed] [Google Scholar]
  28. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Groopman J. E., Mitsuyasu R. T., DeLeo M. J., Oette D. H., Golde D. W. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987 Sep 3;317(10):593–598. doi: 10.1056/NEJM198709033171003. [DOI] [PubMed] [Google Scholar]
  30. Hamaoka T., Ono S. Regulation of B-cell differentiation: interactions of factors and corresponding receptors. Annu Rev Immunol. 1986;4:167–204. doi: 10.1146/annurev.iy.04.040186.001123. [DOI] [PubMed] [Google Scholar]
  31. Hemmi H., Nakamura T., Tamura K., Shimizu Y., Kato S., Miki T., Takahashi N., Muramatsu M., Numao N., Sugamura K. Lymphotoxin: induction of terminal differentiation of the human myeloid leukemia cell lines HL-60 and THP-1. J Immunol. 1987 Feb 1;138(3):664–666. [PubMed] [Google Scholar]
  32. Hirano T., Taga T., Nakano N., Yasukawa K., Kashiwamura S., Shimizu K., Nakajima K., Pyun K. H., Kishimoto T. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985 Aug;82(16):5490–5494. doi: 10.1073/pnas.82.16.5490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hirano T., Taga T., Yasukawa K., Nakajima K., Nakano N., Takatsuki F., Shimizu M., Murashima A., Tsunasawa S., Sakiyama F. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A. 1987 Jan;84(1):228–231. doi: 10.1073/pnas.84.1.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986 Nov 6;324(6092):73–76. doi: 10.1038/324073a0. [DOI] [PubMed] [Google Scholar]
  35. Ho D. D., Pomerantz R. J., Kaplan J. C. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med. 1987 Jul 30;317(5):278–286. doi: 10.1056/NEJM198707303170505. [DOI] [PubMed] [Google Scholar]
  36. Holán V. Successful induction of specific hyporeactivity to rat skin xenografts in newborn mice. Effect of immunoregulatory molecules. Transplantation. 1987 Dec;44(6):809–812. [PubMed] [Google Scholar]
  37. Ihle J. N., Weinstein Y. Immunological regulation of hematopoietic/lymphoid stem cell differentiation by interleukin 3. Adv Immunol. 1986;39:1–50. doi: 10.1016/s0065-2776(08)60347-8. [DOI] [PubMed] [Google Scholar]
  38. Jeevan A., Asherson G. L. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Infect Immun. 1988 Mar;56(3):660–664. doi: 10.1128/iai.56.3.660-664.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Jelinek D. F., Lipsky P. E. Regulation of human B lymphocyte activation, proliferation, and differentiation. Adv Immunol. 1987;40:1–59. doi: 10.1016/s0065-2776(08)60237-0. [DOI] [PubMed] [Google Scholar]
  40. Jíra M., Malkovský M., Denman A. M., Loveland B., Lyons D., Dalgleish A. G., Webster A. D. Lymphokine-activated killer cell activity in rheumatoid arthritis. Clin Exp Immunol. 1987 Jun;68(3):535–542. [PMC free article] [PubMed] [Google Scholar]
  41. Kawamura H., Rosenberg S. A., Berzofsky J. A. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med. 1985 Jul 1;162(1):381–386. doi: 10.1084/jem.162.1.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Kaye W. A., Adri M. N., Soeldner J. S., Rabinowe S. L., Kaldany A., Kahn C. R., Bistrian B., Srikanta S., Ganda O. P., Eisenbarth G. S. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med. 1986 Oct 9;315(15):920–924. doi: 10.1056/NEJM198610093151502. [DOI] [PubMed] [Google Scholar]
  43. Kinashi T., Harada N., Severinson E., Tanabe T., Sideras P., Konishi M., Azuma C., Tominaga A., Bergstedt-Lindqvist S., Takahashi M. Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II. Nature. 1986 Nov 6;324(6092):70–73. doi: 10.1038/324070a0. [DOI] [PubMed] [Google Scholar]
  44. Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev Immunol. 1985;3:133–157. doi: 10.1146/annurev.iy.03.040185.001025. [DOI] [PubMed] [Google Scholar]
  45. Lee F., Yokota T., Otsuka T., Meyerson P., Villaret D., Coffman R., Mosmann T., Rennick D., Roehm N., Smith C. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc Natl Acad Sci U S A. 1986 Apr;83(7):2061–2065. doi: 10.1073/pnas.83.7.2061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lehtonen L., Vainio O., Toivanen P. Mechanisms of transplantation tolerance in B-cell-chimeric chickens. Impairment of tolerance by T cell growth factor. Transplantation. 1986 Aug;42(2):184–191. doi: 10.1097/00007890-198608000-00016. [DOI] [PubMed] [Google Scholar]
  47. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  48. Lotze M. T., Chang A. E., Seipp C. A., Simpson C., Vetto J. T., Rosenberg S. A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA. 1986 Dec 12;256(22):3117–3124. [PubMed] [Google Scholar]
  49. Loughnan M. S., Takatsu K., Harada N., Nossal G. J. T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5399–5403. doi: 10.1073/pnas.84.15.5399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Loveland B., Hunt R., Malkovský M. Autologous lymphoid cells exposed to recombinant interleukin-2 in vitro in the absence of antigen can induce the rejection of long-term tolerated skin allografts. Immunology. 1986 Sep;59(1):159–161. [PMC free article] [PubMed] [Google Scholar]
  51. Malkovska V., Murphy J., Hudson L., Bevan D. Direct effect of interleukin 2 on chronic lymphocytic leukaemia B cell functions and morphology. Clin Exp Immunol. 1987 Jun;68(3):677–684. [PMC free article] [PubMed] [Google Scholar]
  52. Malkovsky M., Asherson G. L., Stockinger B., Watkins M. C. Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature. 1982 Dec 16;300(5893):652–655. doi: 10.1038/300652a0. [DOI] [PubMed] [Google Scholar]
  53. Malkovský M., Edwards A. J., Hunt R., Palmer L., Medawar P. B. T-cell-mediated enhancement of host-versus-graft reactivity in mice fed a diet enriched in vitamin A acetate. Nature. 1983 Mar 24;302(5906):338–340. doi: 10.1038/302338a0. [DOI] [PubMed] [Google Scholar]
  54. Malkovský M., Jíra M., Gao L., Loveland B., Malkovska V., Dalgleish A. G., Webster A. D. Reduced expression of interleukin-2 receptors in hypogammaglobulinaemia: a possible cause of higher cancer incidence. Lancet. 1986 Jun 21;1(8495):1442–1443. doi: 10.1016/s0140-6736(86)91586-2. [DOI] [PubMed] [Google Scholar]
  55. Malkovský M., Jíra M., Madar J., Malkovska V., Loveland B., Asherson G. L. Generation of lymphokine-activated killer cells does not require DNA synthesis. Immunology. 1987 Mar;60(3):471–473. [PMC free article] [PubMed] [Google Scholar]
  56. Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
  57. Malkovský M., Medawar P. B., Thatcher D. R., Toy J., Hunt R., Rayfield L. S., Doré C. Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci U S A. 1985 Jan;82(2):536–538. doi: 10.1073/pnas.82.2.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Malkovský M., Medawar P., Hunt R., Palmer L., Doré C. A diet enriched in vitamin A acetate or in vivo administration of interleukin-2 can counteract a tolerogenic stimulus. Proc R Soc Lond B Biol Sci. 1984 Feb 22;220(1221):439–445. doi: 10.1098/rspb.1984.0012. [DOI] [PubMed] [Google Scholar]
  59. Malkovský M., Sondel P. M. Interleukin 2 and its receptor: structure, function and therapeutic potential. Blood Rev. 1987 Dec;1(4):254–266. doi: 10.1016/0268-960x(87)90027-0. [DOI] [PubMed] [Google Scholar]
  60. March C. J., Mosley B., Larsen A., Cerretti D. P., Braedt G., Price V., Gillis S., Henney C. S., Kronheim S. R., Grabstein K. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985 Jun 20;315(6021):641–647. doi: 10.1038/315641a0. [DOI] [PubMed] [Google Scholar]
  61. Matsumoto M., Tominaga A., Harada N., Takatsu K. Role of T cell-replacing factor (TRF) in the murine B cell differentiation: induction of increased levels of expression of secreted type IgM mRNA. J Immunol. 1987 Mar 15;138(6):1826–1833. [PubMed] [Google Scholar]
  62. Murray H. W., Welte K., Jacobs J. L., Rubin B. Y., Mertelsmann R., Roberts R. B. Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest. 1985 Nov;76(5):1959–1964. doi: 10.1172/JCI112194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Männel D. N. Biological aspects of tumor necrosis factor. Immunobiology. 1986 Sep;172(3-5):283–290. doi: 10.1016/S0171-2985(86)80110-3. [DOI] [PubMed] [Google Scholar]
  64. Nabavi N., Murphy J. W. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun. 1986 Feb;51(2):556–562. doi: 10.1128/iai.51.2.556-562.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Namen A. E., Lupton S., Hjerrild K., Wignall J., Mochizuki D. Y., Schmierer A., Mosley B., March C. J., Urdal D., Gillis S. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature. 1988 Jun 9;333(6173):571–573. doi: 10.1038/333571a0. [DOI] [PubMed] [Google Scholar]
  66. Nienhuis A. W., Donahue R. E., Karlsson S., Clark S. C., Agricola B., Antinoff N., Pierce J. E., Turner P., Anderson W. F., Nathan D. G. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest. 1987 Aug;80(2):573–577. doi: 10.1172/JCI113106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. O'Garra A., Umland S., De France T., Christiansen J. 'B-cell factors' are pleiotropic. Immunol Today. 1988 Feb;9(2):45–54. doi: 10.1016/0167-5699(88)91259-5. [DOI] [PubMed] [Google Scholar]
  68. O'Garra A., Warren D. J., Holman M., Popham A. M., Sanderson C. J., Klaus G. G. Interleukin 4 (B-cell growth factor II/eosinophil differentiation factor) is a mitogen and differentiation factor for preactivated murine B lymphocytes. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5228–5232. doi: 10.1073/pnas.83.14.5228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Ochoa A. C., Gromo G., Alter B. J., Sondel P. M., Bach F. H. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol. 1987 Apr 15;138(8):2728–2733. [PubMed] [Google Scholar]
  70. Paul N. L., Ruddle N. H. Lymphotoxin. Annu Rev Immunol. 1988;6:407–438. doi: 10.1146/annurev.iy.06.040188.002203. [DOI] [PubMed] [Google Scholar]
  71. Paul W. E., Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol. 1987;5:429–459. doi: 10.1146/annurev.iy.05.040187.002241. [DOI] [PubMed] [Google Scholar]
  72. Pestka S., Langer J. A., Zoon K. C., Samuel C. E. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777. doi: 10.1146/annurev.bi.56.070187.003455. [DOI] [PubMed] [Google Scholar]
  73. Pizza G., Severini G., Menniti D., De Vinci C., Corrado F. Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer. 1984 Sep 15;34(3):359–367. doi: 10.1002/ijc.2910340312. [DOI] [PubMed] [Google Scholar]
  74. Rappaport R. S., Dodge G. R. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med. 1982 Mar 1;155(3):943–948. doi: 10.1084/jem.155.3.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Rawle F. C., Shields J., Smith S. H., Iliescu V., Merkenschlager M., Beverley P. C., Callard R. E. B cell growth and differentiation induced by supernatants of transformed epithelial cell lines. Eur J Immunol. 1986 Aug;16(8):1017–1019. doi: 10.1002/eji.1830160825. [DOI] [PubMed] [Google Scholar]
  76. Reinherz E. L. T-cell receptors. Who needs more? Nature. 1987 Feb 19;325(6106):660–663. doi: 10.1038/325660a0. [DOI] [PubMed] [Google Scholar]
  77. Robb R. J., Greene W. C. Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. J Exp Med. 1987 Apr 1;165(4):1201–1206. doi: 10.1084/jem.165.4.1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  79. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  80. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  81. Rosenberg S. A. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin Oncol. 1986 Jun;13(2):200–206. [PubMed] [Google Scholar]
  82. Sanderson C. J., O'Garra A., Warren D. J., Klaus G. G. Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. Proc Natl Acad Sci U S A. 1986 Jan;83(2):437–440. doi: 10.1073/pnas.83.2.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Sanderson C. J., Warren D. J., Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J Exp Med. 1985 Jul 1;162(1):60–74. doi: 10.1084/jem.162.1.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Schrader J. W. The panspecific hemopoietin of activated T lymphocytes (interleukin-3). Annu Rev Immunol. 1986;4:205–230. doi: 10.1146/annurev.iy.04.040186.001225. [DOI] [PubMed] [Google Scholar]
  85. Sideras P., Noma T., Honjo T. Structure and function of interleukin 4 and 5. Immunol Rev. 1988 Feb;102:189–212. doi: 10.1111/j.1600-065x.1988.tb00745.x. [DOI] [PubMed] [Google Scholar]
  86. Siegel J. P., Sharon M., Smith P. L., Leonard W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 1987 Oct 2;238(4823):75–78. doi: 10.1126/science.3116668. [DOI] [PubMed] [Google Scholar]
  87. Socinski M. A., Cannistra S. A., Elias A., Antman K. H., Schnipper L., Griffin J. D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28;1(8596):1194–1198. doi: 10.1016/s0140-6736(88)92012-0. [DOI] [PubMed] [Google Scholar]
  88. Sohmura Y., Nakata K., Yoshida H., Kashimoto S., Matsui Y., Furuichi H. Recombinant human tumor necrosis factor--II. Antitumor effect on murine and human tumors transplanted in mice. Int J Immunopharmacol. 1986;8(3):357–368. doi: 10.1016/0192-0561(86)90118-9. [DOI] [PubMed] [Google Scholar]
  89. Sondel P. M., Hank J. A., Kohler P. C., Chen B. P., Minkoff D. Z., Molenda J. A. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol. 1986 Jul 15;137(2):502–511. [PubMed] [Google Scholar]
  90. Sondel P. M., Hank J. A., Wendel T., Flynn B., Bozdech M. J. HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro. J Clin Invest. 1983 Jun;71(6):1779–1786. doi: 10.1172/JCI110933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Swain S. L., Dutton R. W. Production of a B cell growth-promoting activity, (DL)BCGF, from a cloned T cell line and its assay on the BCL1 B cell tumor. J Exp Med. 1982 Dec 1;156(6):1821–1834. doi: 10.1084/jem.156.6.1821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Swain S. L., Howard M., Kappler J., Marrack P., Watson J., Booth R., Wetzel G. D., Dutton R. W. Evidence for two distinct classes of murine B cell growth factors with activities in different functional assays. J Exp Med. 1983 Sep 1;158(3):822–835. doi: 10.1084/jem.158.3.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Swain S. L. Role of BCGFII in the differentiation to antibody secretion normal and tumor B cells. J Immunol. 1985 Jun;134(6):3934–3943. [PubMed] [Google Scholar]
  94. Takatsu K., Kikuchi Y., Takahashi T., Honjo T., Matsumoto M., Harada N., Yamaguchi N., Tominaga A. Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4234–4238. doi: 10.1073/pnas.84.12.4234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Thurman G. B., Maluish A. E., Rossio J. L., Schlick E., Onozaki K., Talmadge J. E., Procopio A. D., Ortaldo J. R., Ruscetti F. W., Stevenson H. C. Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations. J Biol Response Mod. 1986 Feb;5(1):85–107. [PubMed] [Google Scholar]
  96. Toyonaga B., Mak T. W. Genes of the T-cell antigen receptor in normal and malignant T cells. Annu Rev Immunol. 1987;5:585–620. doi: 10.1146/annurev.iy.05.040187.003101. [DOI] [PubMed] [Google Scholar]
  97. Trinchieri G., Kobayashi M., Rosen M., Loudon R., Murphy M., Perussia B. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med. 1986 Oct 1;164(4):1206–1225. doi: 10.1084/jem.164.4.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Tsang K. Y., Fudenberg H. H., Galbraith G. M., Donnelly R. P., Bishop L. R., Koopmann W. R. Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro. J Clin Invest. 1985 May;75(5):1538–1544. doi: 10.1172/JCI111858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Tsudo M., Goldman C. K., Bongiovanni K. F., Chan W. C., Winton E. F., Yagita M., Grimm E. A., Waldmann T. A. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5394–5398. doi: 10.1073/pnas.84.15.5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Urban J. L., Shepard H. M., Rothstein J. L., Sugarman B. J., Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5233–5237. doi: 10.1073/pnas.83.14.5233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1450–1466. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Waldmann T. A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986 May 9;232(4751):727–732. doi: 10.1126/science.3008337. [DOI] [PubMed] [Google Scholar]
  103. Weiss A., Imboden J., Hardy K., Manger B., Terhorst C., Stobo J. The role of the T3/antigen receptor complex in T-cell activation. Annu Rev Immunol. 1986;4:593–619. doi: 10.1146/annurev.iy.04.040186.003113. [DOI] [PubMed] [Google Scholar]
  104. Welte K., Ciobanu N., Moore M. A., Gulati S., O'Reilly R. J., Mertelsmann R. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood. 1984 Aug;64(2):380–385. [PubMed] [Google Scholar]
  105. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  106. Wong-Staal F., Gallo R. C. Human T-lymphotropic retroviruses. Nature. 1985 Oct 3;317(6036):395–403. doi: 10.1038/317395a0. [DOI] [PubMed] [Google Scholar]
  107. Wong G. G., Clark S. C. Multiple actions of interleukin 6 within a cytokine network. Immunol Today. 1988 May;9(5):137–139. doi: 10.1016/0167-5699(88)91200-5. [DOI] [PubMed] [Google Scholar]
  108. Yang Y. C., Ciarletta A. B., Temple P. A., Chung M. P., Kovacic S., Witek-Giannotti J. S., Leary A. C., Kriz R., Donahue R. E., Wong G. G. Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell. 1986 Oct 10;47(1):3–10. doi: 10.1016/0092-8674(86)90360-0. [DOI] [PubMed] [Google Scholar]
  109. Yokota T., Arai N., de Vries J., Spits H., Banchereau J., Zlotnik A., Rennick D., Howard M., Takebe Y., Miyatake S. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol Rev. 1988 Feb;102:137–187. doi: 10.1111/j.1600-065x.1988.tb00744.x. [DOI] [PubMed] [Google Scholar]
  110. de Boer R. J., Hogeweg P. Immunological discrimination between self and non-self by precursor depletion and memory accumulation. J Theor Biol. 1987 Feb 7;124(3):343–369. doi: 10.1016/s0022-5193(87)80121-2. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES